A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320

Leuk Lymphoma. 2016 Sep;57(9):2232-4. doi: 10.3109/10428194.2015.1133814. Epub 2016 Mar 22.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / adverse effects
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Humans
  • Immunoblastic Lymphadenopathy / drug therapy*
  • Immunoblastic Lymphadenopathy / mortality
  • Immunoblastic Lymphadenopathy / pathology
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / mortality
  • Lymphoma, T-Cell / pathology
  • Male
  • Middle Aged
  • Survival Analysis
  • Thalidomide / administration & dosage*
  • Thalidomide / adverse effects
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives*

Substances

  • Thalidomide
  • Cyclophosphamide
  • Vidarabine
  • fludarabine